Alain Mina, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 Room 6N119
- Bethesda, MD 20892
- 240-858-7625
- alain.mina@nih.gov
RESEARCH SUMMARY
My research focuses on identifying signaling pathways that promote leukemogenesis in myeloid malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia as well as developing targeted therapies that could be brought forth into clinical trials. Goal would be to move towards a chemotherapy-free targeted treatment strategy. Other modalities to achieve that goal would be the development of chimeric antigen receptor (CAR) T cells (targeting myeloid cell antigens such as CLL-1, CD123, CD33, etc.), bispecific T cell engagers (BiTE) and immune checkpoint blockade.
Areas of Expertise
Cell Therapy
Stem Cell Transplant
Myeloid Malignancies
Myelodysplastic Syndromes (MDS)
Acute Myelogenous Leukemia (AML)
Drug Development
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Alain Mina, M.D.
Research
My research efforts primarily focus on:
- Understanding the role of aberrant signal transduction pathways in the development of myeloid neoplasms.
- Defining molecular targets for the treatment of leukemia.
- Preclinical MDS/AML models design
- Preclinical drug development and early phase trials design.
- Translating adult stem cell laboratory research findings into clinical interventions with focus on myeloid malignancies.
- Translating the success of cellular therapies in B-cell lymphomas into the realm of myeloid neoplasms.
Publications
Selected Key Publications
Inhibitory effects of Tomivosertib in acute myeloid leukemia
Oncotarget.
12:
955-966,
2021.
[ Journal Article ]
Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?
Curr Hematol Malign Reports.
14:
137-144,
2019.
[ Journal Article ]
Inhibitory effects of SEL201 in acute myeloid leukemia
Oncotarget.
10:
7112-7121,
2019.
[ Journal Article ]
Use of hyperbaric oxygen in hematopoietic cell transplantation to aid post-transplant recovery
J Comp Eff Res.
9:
149-153,
2020.
[ Journal Article ]
Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study
Biol Blood Marrow Transplant.
24:
400-405,
2018.
[ Journal Article ]